Cystic Fibrosis: all 1,605 studies

Page 3 of 17. Open to participants first (196), then studies with results posted, then the rest; newest registration first within each.

• Phase 1 Study to Assess Safety and Efficacy of ANG003CompletedNCT06052293Phase 1Results posted
• Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgeCompletedNCT05882357Phase 3Results posted
• A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)CompletedNCT05865886Phase 2Results posted
• Semaglutide in CFRDCompletedNCT05788965Phase 2/3Results posted
• Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic FibrosisCompletedNCT05740618Phase 4Results posted
• Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic FibrosisCompletedNCT05719311Phase 2Results posted
• Neuromodulation for Children With Cystic Fibrosis Experiencing Chronic Abdominal PainTerminatedNCT05515250Not applicableResults posted
• A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas AeruginosaCompletedNCT05453578Phase 1/2Results posted
• Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del MutationCompletedNCT05274269Phase 3Results posted
• Feasibility of Home-based Exercise Program for Adults With Cystic FibrosisCompletedNCT05239611Phase 2Results posted
• Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic FibrosisCompletedNCT05225805Phase 1Results posted
• Lung Transplant READY Pilot StudyCompletedNCT05135156Not applicableResults posted
• A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)CompletedNCT05111145Phase 3Results posted
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic FibrosisCompletedNCT05090904Phase 2Results posted
• A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del MutationCompletedNCT05076149Phase 3Results posted
• Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With CreonCompletedNCT05069597Phase 4Results posted
• A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)CompletedNCT05033080Phase 3Results posted
• A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)CompletedNCT04969224Phase 3Results posted
• Ketone Supplementation in Cystic FibrosisCompletedNCT04938726Not applicableResults posted
• Cystic Fibrosis and Urinary IncontinenceTerminatedNCT04922255Not applicableResults posted
• Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPDTerminatedNCT04921332Not applicableResults posted
• Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against InfectionsCompletedNCT04884308Phase 2Results posted
• Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic FibrosisTerminatedNCT04853368Phase 2Results posted
• Airway Clearance for Pediatric and Adult Cystic Fibrosis Patients Using a Portable Intra-Pulmonary Percussion DeviceTerminatedNCT04743206Not applicableResults posted
• Pilocarpine Microneedles for Sweat Induction (PMN-SI)CompletedNCT04732195Not applicableResults posted
• CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)CompletedNCT04684641Phase 1/2Results posted
• A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)CompletedNCT04599465Phase 3Results posted
• Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic FibrosisCompletedNCT04596319Phase 1/2Results posted
• A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF GenotypesCompletedNCT04545515Phase 3Results posted
• Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 YearsCompletedNCT04537793Phase 3Results posted
• Pharmacokinetics of Omadacycline in Cystic FibrosisCompletedNCT04460586Phase 4Results posted
• Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator TherapyCompletedNCT04378153Results posted
• OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic FibrosisCompletedNCT04375878Phase 2Results posted
• Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic FibrosisTerminatedNCT04375514Phase 1/2Results posted
• A Study Evaluating the Long-Term Safety of Elexacaftor Combination TherapyCompletedNCT04362761Phase 3Results posted
• A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF GenotypesCompletedNCT04353817Phase 3Results posted
• Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment InitiationCompletedNCT04235140Phase 3Results posted
• Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal TransitCompletedNCT04210427Phase 4Results posted
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and OlderCompletedNCT04183790Phase 3Results posted
• Vitamin D and Prebiotics for Intestinal Health in Cystic FibrosisCompletedNCT04118010Phase 4Results posted
• A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508delCompletedNCT04105972Phase 3Results posted
• A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1TerminatedNCT04059094Phase 2Results posted
• Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedNCT04058366Phase 3Results posted
• A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)CompletedNCT04058353Phase 3Results posted
• A Study Evaluating the Long-term Safety of VX-445 Combination TherapyCompletedNCT04043806Phase 3Results posted
• Sildenafil Exercise: Role of PDE5 InhibitionCompletedNCT04039087Phase 2/3Results posted
• STeP IT UP CF: STimulating ImProved Health And Well-being In CysTic FibrosisCompletedNCT04018495Results posted
• A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222CompletedNCT03969888Phase 2Results posted
• Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic ConditionsCompletedNCT03938324Not applicableResults posted
• A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic FibrosisCompletedNCT03924947Phase 4Results posted
• A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic FibrosisCompletedNCT03912233Phase 2Results posted
• A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic FibrosisCompletedNCT03911713Phase 2Results posted
• Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension PhaseCompletedNCT03905642Phase 2Results posted
• A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus SecretionsCompletedNCT03843541Phase 3Results posted
• Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic FibrosisCompletedNCT03801993Results posted
• MN4000 for Treatment of CF and MND Patients in the Home SettingCompletedNCT03797677Not applicableResults posted
• Study of VX-121 in Healthy Subjects and in Subjects With Cystic FibrosisCompletedNCT03768089Phase 1/2Results posted
• OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic FibrosisCompletedNCT03746483Phase 2Results posted
• Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General AnesthesiaCompletedNCT03734822Not applicableResults posted
• Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of AgeCompletedNCT03691779Phase 3Results posted
• Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of AgeTerminatedNCT03633526Phase 3Results posted
• Effect of HFCWO Vests on Spirometry MeasurementsCompletedNCT03628456Not applicableResults posted
• A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508delCompletedNCT03625466Phase 2Results posted
• Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon MutationsTerminatedNCT03624101Phase 4Results posted
• Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508delCompletedNCT03601637Phase 3Results posted
• Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial InfectionTerminatedNCT03597347Phase 2Results posted
• Gut Imaging for Function & Transit in Cystic Fibrosis Study 1CompletedNCT03566550Results posted
• A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic FibrosisCompletedNCT03559062Phase 3Results posted
• Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)CompletedNCT03551691Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR MutationCompletedNCT03537651Phase 3Results posted
• Effect of High Frequency Chest Wall Oscillation Vests on Spirometry MeasurementsCompletedNCT03534986Not applicableResults posted
• A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedNCT03525574Phase 3Results posted
• A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)CompletedNCT03525548Phase 3Results posted
• A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)CompletedNCT03525444Phase 3Results posted
• Trikafta in Cystic Fibrosis PatientsCompletedNCT03506061Phase 2Results posted
• Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo CapsulesCompletedNCT03502070Phase 4Results posted
• STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)CompletedNCT03489629Phase 2Results posted
• A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)CompletedNCT03460990Phase 3Results posted
• Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisCompletedNCT03451045Phase 2Results posted
• A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination TherapyTerminatedNCT03447262Phase 3Results posted
• A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)CompletedNCT03447249Phase 3Results posted
• : TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)CompletedNCT03445793Results posted
• Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic FibrosisCompletedNCT03375047Phase 1/2Results posted
• Clinical Effects of Exercise Program Added to Pulmonary Rehabilitation in Patients With Cystic FibrosisCompletedNCT03295201Not applicableResults posted
• A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive MutationCompletedNCT03277196Phase 3Results posted
• Study of LAU-7b in the Treatment of Cystic Fibrosis in AdultsCompletedNCT03265288Phase 2Results posted
• Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related DiabetesCompletedNCT03258853Not applicableResults posted
• PTC Study to Evaluate Ataluren in Combination With IvacaftorCompletedNCT03256968Phase 4Results posted
• Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense MutationsCompletedNCT03256799Phase 4Results posted
• An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic FibrosisCompletedNCT03229252Phase 2Results posted
• A Study of VX-445 in Healthy Subjects and Subjects With Cystic FibrosisCompletedNCT03227471Phase 1/2Results posted
• A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic FibrosisCompletedNCT03224351Phase 2Results posted
• Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa BacteriaTerminatedNCT03219164Phase 3Results posted
• Losartan and Inflammation in Cystic FibrosisTerminatedNCT03206788Phase 2Results posted
• AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic FibrosisCompletedNCT03181932Phase 3Results posted
• A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)CompletedNCT03150719Phase 3Results posted
• A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedNCT03125395Phase 3Results posted
• A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic FibrosisCompletedNCT03119649Phase 2Results posted
• Clearance of 25-hydroxyvitamin D in Cystic FibrosisCompletedNCT03104855Phase 1Results posted
• Researching the Effects of Airway Clearance Therapies in Cystic FibrosisCompletedNCT03078127Not applicableResults posted

← Cystic Fibrosis overview